Business
Astria Stockholders Vote to Approve Acquisition by BioCryst
BOSTON, January 21, 2026--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger").
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3945,"height":1189,"url":"https://media.zenfs.com/en/business-wire.com/b0ef62810377fba5fcbfc85d3c91a132"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/77.6CbeHTSDoOuD26yVkvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0ef62810377fba5fcbfc85d3c91a132","width":960,"height":289},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Tbma9Hvr7Lr8evuBOyOwow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b0ef62810377fba5fcbfc85d3c91a132","width":1200,"height":362}},"lazy":false},{"type":"text","content":"BOSTON, January 21, 2026--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the "Merger").","length":303,"tagName":"p"},{"type":"text","content":"The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.","length":129,"tagName":"p"},{"type":"text","content":"About Astria Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Astria’s second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis.","length":506,"tagName":"p"},{"type":"text","content":"Cautionary Note Regarding Forward-Looking Statements","length":52,"tagName":"p"},{"type":"text","content":"Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Ac...